Karuna Therapeutics KRTX

HealthcareMarket cap $13B1 connection

Karuna Therapeutics developed KarXT (xanomeline-trospium) - the first truly novel antipsychotic mechanism in decades, acting on muscarinic receptors rather than dopamine. It was acquired by Bristol-Myers Squibb for $14B in 2024. KarXT could replace older antipsychotics that cause severe weight gain and tardive dyskinesia in schizophrenia patients.

Explore Karuna Therapeutics on the interactive map Relationship timeline Find a path to another company

Owned by 1

Companies with a stake in Karuna Therapeutics

Bristol-Myers SquibbHealthcare · $140BBristol-Myers Squibb acquired Karuna for $14Bsince 2024

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Karuna Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=KRTX" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Karuna Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.